Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Want to see JAGX full AI Analyst Report?
JAGX Stock Chart & Stats
$1.28
-$0.07(-5.93%)
At close: 4:00 PM EST
$1.28
-$0.07(-5.93%)
Day’s Range― - ―
52-Week Range$2.53 - $144.55
Previous CloseN/A
Volume188.05K
Average Volume (3M)117.24K
Market Cap
$1.94M
Enterprise Value$27.27M
Total Cash (Recent Filing)$7.28M
Total Debt (Recent Filing)$34.31M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-708.88
Shares Outstanding603,134
10 Day Avg. Volume154,544
30 Day Avg. Volume117,236
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.13
Price to Sales (P/S)0.19
P/FCF Ratio0.38
Enterprise Value/Market Cap14.04
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit1.08
Enterprise Value/Ebitda-0.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.2
Revenue Forecast (FY)$2.46M
Bulls Say, Bears Say
Bulls Say
Commercial Product With Healthy Gross MarginsJaguar has an FDA-approved, commercial-stage product (Mytesi) with durable product economics reflected in ~58% gross margins. Strong product-level margins provide a structural buffer to fund commercialization and development if revenue stabilizes or scales, supporting long-term profitability potential.
Material Out-licensing Partnership Driving RevenueThe Future Pak out-license produced an outsized, recurring-style revenue lift (816% YoY in Q1 2026), demonstrating the company's ability to monetize Mytesi via third-party commercialization. Such licensing partnerships create durable non-dilutive cash flow and validation for broader commercial strategies and pipeline support.
Debt And Royalty Restructuring Improving Near-term LiquidityManagement has restructured royalty and note obligations, cutting repayment amounts and deferring timing while lowering certain balances. These contractual changes materially reduce near-term cash outflows and push maturities, improving the company’s runway and lowering immediate refinancing risk versus pre-amendment terms.
Bears Say
Negative Equity And High LeverageA persistent stockholders’ deficit and elevated debt relative to modest revenue materially constrain financial flexibility. Negative equity impairs borrowing capacity, can trigger covenant issues, and raises the probability the firm must rely on dilutive financing or onerous creditor concessions to fund operations over the medium term.
Renewed Negative Operating And Free Cash FlowThe return to negative operating and free cash flow after a prior positive year indicates unstable cash generation. Continued cash burn elevates the need for external financing, increases dilution risk, and limits the company's ability to self-fund development or commercial expansion without materially altering capital structure or partner terms.
Restrictive Preferred Instruments And Governance CovenantsIssuance of Series Q preferred with strong investor protections, consent rights, and constraints on new equity or indebtedness reduces strategic flexibility. These durable governance and liquidation terms can limit management options, increase future dilution risk, and shift control dynamics over multi-quarter planning horizons.
Jaguar Animal Health News
JAGX FAQ
What was Jaguar Animal Health Inc.’s price range in the past 12 months?
Jaguar Animal Health Inc. lowest stock price was $2.53 and its highest was $144.55 in the past 12 months.
What is Jaguar Animal Health Inc.’s market cap?
Jaguar Animal Health Inc.’s market cap is $1.94M.
When is Jaguar Animal Health Inc.’s upcoming earnings report date?
Jaguar Animal Health Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 75 days.
How were Jaguar Animal Health Inc.’s earnings last quarter?
Currently, no data Available
Is Jaguar Animal Health Inc. overvalued?
According to Wall Street analysts Jaguar Animal Health Inc.’s price is currently Overvalued.
Does Jaguar Animal Health Inc. pay dividends?
Jaguar Animal Health Inc. does not currently pay dividends.
What is Jaguar Animal Health Inc.’s EPS estimate?
Jaguar Animal Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jaguar Animal Health Inc. have?
Jaguar Animal Health Inc. has 603,134 shares outstanding.
What happened to Jaguar Animal Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Jaguar Animal Health Inc.?
Currently, no hedge funds are holding shares in JAGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jaguar Animal Health Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
JAGX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.View all JAGX earnings summariesTechnical Analysis
Galmed Pharmaceuticals
―
Soligenix
―
Revelation Biosciences
―
Dermata Therapeutics
―
60 Degrees Pharmaceuticals, Inc.
―
Ownership Overview
17.26% Insiders
10.07% Mutual Funds
― Other Institutional Investors
72.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---